Dyno Therapeutics, a genetic technologies company focused on applying Artificial Intelligence (AI) to advance in vivo gene delivery, has launched of two new Adeno-Associated Virus (AAV) gene delivery capsids designed for Central Nervous System (CNS) and muscle-targeted therapies. The company also revealed updated in vivo data for its previously released capsids, Dyno-yp2 for CNS delivery and Dyno-bn8 for muscle delivery, during its Scientific Symposium at the 29th Annual Meeting of the American Society of Gene and Cell Therapy.

The newly launched capsids were developed using Dyno’s AI-powered platform, which integrates advanced AI agents and foundation models with large-scale biological datasets to accelerate the development of genetic medicines. According to the company, the platform has been trained on billions of in vivo non-human primate measurements, enabling the engineering of AAV capsids with improved tissue selectivity, liver detargeting, cross-species translatability and manufacturability.

Efficient and selective gene delivery remains one of the major challenges in gene therapy, particularly as many therapies require high doses that can increase safety risks, raise treatment costs and restrict broader patient access. Dyno said its AI-driven approach aims to address these limitations by creating delivery vectors with improved performance and scalability.

Commenting on the development, Eric Kelsic, Chief Executive Officer and Co-Founder, Dyno Therapeutics, said, “Each newly launched capsid demonstrates the company’s ability to combine deep biological understanding with large-scale in vivo experimentation and advanced AI-based protein design. Dyno’s growing portfolio provides partners with greater flexibility and confidence in identifying suitable delivery vectors for gene therapy programmes.

Among the key launches, Dyno introduced Dyno-9zh, an AAV capsid engineered for efficient blood-brain barrier crossing and widespread CNS transduction following intravenous administration across humans, non-human primates and mice. The capsid is designed to bind to human alkaline phosphatase and showed strong cross-species performance in preclinical studies.

According to the company, Dyno-9zh demonstrated CNS transduction efficiency and liver detargeting comparable to TTM-027 in non-human primates, while delivering nearly twice the CNS transduction efficiency in mice. At a dose of 3×10¹³ vg/kg, the capsid achieved broad transduction across the brain and spinal cord in non-human primates, including transduction of up to 50 percent of neurons in the premotor cortex.

The company also reported significantly lower liver biodistribution compared to AAV9 in both non-human primates and mice, potentially reducing off-target effects and safety concerns. In addition, Dyno-9zh is compatible with existing AAV9 production processes, supporting scalable and cost-effective manufacturing.

Dyno Therapeutics said the continued expansion of its AI-engineered capsid portfolio reflects growing momentum in the use of computational biology and machine learning to improve the precision, safety and accessibility of next-generation gene therapies.